Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
Want to see KPRX full AI Analyst Report?
KPRX Stock Chart & Stats
$1.91
-$0.13(-3.22%)
At close: 4:00 PM EST
$1.91
-$0.13(-3.22%)
Day’s Range― - ―
52-Week Range$1.76 - $4.18
Previous CloseN/A
Volume13.46K
Average Volume (3M)36.18K
Market Cap
$9.17M
Enterprise Value$876.66K
Total Cash (Recent Filing)$17.09M
Total Debt (Recent Filing)$368.26K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 08, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.59
Shares Outstanding3,950,628
10 Day Avg. Volume38,148
30 Day Avg. Volume36,176
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-17.99
Enterprise Value/Ebitda-0.09
Forecast
1Y Price Target
$12.00Price Target Upside528.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.34
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Capital BaseVery low debt-to-equity (~0.02) and $16.1M of equity reduce solvency risk and preserve financial flexibility. This durable balance-sheet strength supports continued R&D spending, partner negotiations and lowers bankruptcy probability while clinical programs advance.
Committed Near-term FundingThe $5M upfront private placement and potential $19M from warrant exercise materially extend near-term runway. Registered resale and strategic investor support improve funding continuity for R&D and trial execution, reducing immediate financing pressure and enabling milestone-driven development.
Advancing Clinical PipelineProgress in ABACUS-2 and KLARITY—cohort progression, cleared safety checkpoints and ongoing enrollment—lowers execution risk relative to earlier stages. Sustained trial advancement increases the probability of reaching value-driving milestones and strengthens the company’s core development thesis.
Bears Say
No Recent Revenue And Sizable LossesTTM revenue of $0 and a $10.8M net loss show the company lacks commercial income and remains dependent on R&D outcomes. Persistent losses undermine internal funding capacity and make the business reliant on external capital or partnerships to sustain development and operations over the medium term.
Negative Cash GenerationSustained operating cash flow and free cash flow deficits (~-$10M TTM) indicate ongoing cash burn. Weak cash generation forces dependence on dilutive financings or strategic deals, limiting autonomy to invest in programs and increasing execution risk if additional funding is delayed or unavailable.
Key Development Leadership DepartureThe CDO resignation during active trials introduces leadership and continuity risk. Loss of a senior clinical executive can disrupt protocol oversight and institutional knowledge, increase reliance on CROs, and potentially slow enrollment or strategic decisions until an experienced successor is appointed.
Kiora Pharmaceuticals News
KPRX FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was $1.76 and its highest was $4.18 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Kiora Pharmaceuticals’s market cap is $9.17M.
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is May 08, 2026 which is in 8 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on Mar 25, 2026. The company reported -$1.59 earnings per share for the quarter, missing the consensus estimate of -$0.67 by -$0.92.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Undervalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate is -0.71.
How many shares outstanding does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals has 3,950,628 shares outstanding.
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of -$1.59 in its last earnings report, missing expectations of -$0.67. Following the earnings report the stock price went down -0.971%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in KPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
KPRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(528.27% Upside)
Technical Analysis
Genprex
―
Dogwood Therapeutics
―
Sensei Biotherapeutics
―
TransCode Therapeutics
―
AEON Biopharma
―
Ownership Overview
3.02% Insiders
1.18% Mutual Funds
<0.01% Other Institutional Investors
95.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---